This trial is conducted in Europe. The aim of this trial is to test for bioequivalence of the phase 3a formulation of liraglutide (formulation 4) and the liraglutide formulation planned for phase 3b trials (final formulation 4).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
22
Two single doses of 0.72 mg liraglutide administered subcutaneously on two different dosing occasions separated by a wash-out period
Unnamed facility
Lund, Sweden
Area under the curve (0-t)
Cmax, maximum concentration
Area under the curve (0-infinity)
Relative bioavailability
Time to reach maximum (tmax)
Terminal elimination half life (t½)
Terminal elimination rate constant
Adverse events
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.